PHARMA | PHARMANIAGA BHD
0.360 (-1.37%)
T-O (am): 0.000 (08:59:00)
Last updated: 17:00
Fundamental
Technical
Total Score
PHARMA Fundamental Trend
FCON: | Sharpe Ratio: | LTS:
PHARMA Quarter Reports
Customize
Select columns required and click "Update" to save your preferences
| Ann. Date | Qtr. Date | Q | FYE | Revenue [M] | PBT [M] | NP [M] | NPM | DPS | EPS | R. QoQ | R. YoY | E. QoQ | E. YoY | TTM EPS |
Adj. [M] |
NP [M] (adj) |
NPM (adj) |
EPS (adj) |
E. QoQ (adj) |
E. YoY (adj) |
TTM EPS (adj) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 Aug 24 | Q2 Jun 24 | 2 | 31 Dec 24 | 838.26 | 3.33 | 2.80 | 0.3% | 0.00 | 0.19 | 13.1% | 1.2% | 89.1% | 42.6% | ||||||||
| 27 May 24 | Q1 Mar 24 | 1 | 31 Dec 24 | 964.96 | 39.04 | 25.65 | 2.7% | 0.00 | 1.78 | 22.2% | 9.6% | 178.4% | 868.5% | ||||||||
| 29 Feb 24 | Q4 Dec 23 | 4 | 31 Dec 23 | 789.81 | -22.10 | -32.72 | -4.1% | 0.00 | -2.39 | 10.8% | 8.4% | 33.7% | 94.9% | ||||||||
| 29 Nov 23 | Q3 Sep 23 | 3 | 31 Dec 23 | 885.49 | -56.26 | -49.34 | -5.6% | 0.00 | -3.67 | 4.3% | 4.2% | 2616.0% | 672.6% | ||||||||
| 11 Aug 23 | Q2 Jun 23 | 2 | 31 Dec 23 | 848.73 | 6.34 | 1.96 | 0.2% | 0.00 | 0.15 | 3.6% | 11.5% | 25.9% | 171.6% | ||||||||
| 18 May 23 | Q1 Mar 23 | 1 | 31 Dec 23 | 880.45 | 9.19 | 2.65 | 0.3% | 0.00 | 0.20 | 2.1% | 8.5% | 100.4% | 90.5% | ||||||||
| 27 Feb 23 | Q4 Dec 22 | 4 | 31 Dec 22 | 862.72 | -638.39 | -644.39 | -74.7% | 0.00 | -49.19 | 6.7% | 21.2% | 7578.1% | 853.9% | ||||||||
| 24 Nov 22 | Q3 Sep 22 | 3 | 31 Dec 22 | 924.68 | 15.59 | 8.62 | 0.9% | 0.60 | 0.66 | 21.5% | 56.6% | 1093.5% | 82.7% | ||||||||
| 19 Aug 22 | Q2 Jun 22 | 2 | 31 Dec 22 | 761.10 | 4.52 | 0.72 | 0.1% | 0.50 | 0.06 | 20.9% | 35.3% | 97.4% | 94.7% | ||||||||
| 20 May 22 | Q1 Mar 22 | 1 | 31 Dec 22 | 962.17 | 37.44 | 27.73 | 2.9% | 0.80 | 2.12 | 35.2% | 21.3% | 67.5% | 19.9% | ||||||||
| 17 Feb 22 | Q4 Dec 21 | 4 | 31 Dec 21 | 711.72 | 125.09 | 85.47 | 12.0% | 5.00 | 6.53 | 66.6% | 12.2% | 71.5% | 1450.1% | ||||||||
| 19 Nov 21 | Q3 Sep 21 | 3 | 31 Dec 21 | 2,132.68 | 98.22 | 49.84 | 2.3% | 2.00 | 3.81 | 81.2% | 241.3% | 263.6% | 3356.0% | ||||||||
| 20 Aug 21 | Q2 Jun 21 | 2 | 31 Dec 21 | 1,177.12 | 22.24 | 13.70 | 1.2% | 1.50 | 1.05 | 48.4% | 82.3% | 40.8% | 37.3% | ||||||||
| 21 May 21 | Q1 Mar 21 | 1 | 31 Dec 21 | 793.50 | 31.52 | 23.14 | 2.9% | 4.00 | 8.84 | 25.0% | 3.2% | 465.4% | 3.3% | ||||||||
| 17 Mar 21 | Q4 Dec 20 | 4 | 31 Dec 20 | 634.58 | -13.51 | -6.33 | -1.0% | 1.00 | -2.42 | 1.6% | 11.3% | 539.0% | 96.5% | ||||||||
| 19 Nov 20 | Q3 Sep 20 | 3 | 31 Dec 20 | 624.80 | 4.09 | 1.44 | 0.2% | 1.50 | 0.55 | 3.2% | 12.8% | 85.5% | 199.8% | ||||||||
| 19 Aug 20 | Q2 Jun 20 | 2 | 31 Dec 20 | 645.76 | 14.33 | 9.98 | 1.6% | 2.50 | 3.82 | 21.2% | 7.3% | 55.5% | 7.5% | ||||||||
| 19 May 20 | Q1 Mar 20 | 1 | 31 Dec 20 | 819.92 | 30.88 | 22.40 | 2.7% | 6.00 | 8.57 | 14.6% | 4.3% | 112.5% | 14.2% | ||||||||
| 20 Feb 20 | Q4 Dec 19 | 4 | 31 Dec 19 | 715.68 | -238.47 | -178.60 | -24.9% | 0.00 | -68.45 | 0.2% | 19.9% | 37230.6% | 4125.2% | ||||||||
| 20 Nov 19 | Q3 Sep 19 | 3 | 31 Dec 19 | 716.85 | 3.88 | 0.48 | 0.1% | 0.00 | 0.18 | 19.1% | 23.0% | 94.8% | 91.1% | ||||||||
| 23 Aug 19 | Q2 Jun 19 | 2 | 31 Dec 19 | 601.89 | 12.48 | 9.28 | 1.5% | 2.50 | 3.56 | 23.4% | 2.6% | 52.7% | 47.2% | ||||||||
| 16 May 19 | Q1 Mar 19 | 1 | 31 Dec 19 | 786.11 | 30.24 | 19.62 | 2.5% | 6.00 | 7.53 | 31.8% | 28.2% | 342.1% | 9.6% | ||||||||
| 21 Feb 19 | Q4 Dec 18 | 4 | 31 Dec 18 | 596.64 | 11.94 | 4.44 | 0.7% | 2.00 | 1.71 | 2.4% | 3.9% | 17.7% | 23.9% | ||||||||
| 17 Aug 18 | Q2 Jun 18 | 2 | 31 Dec 18 | 582.73 | 11.97 | 5.39 | 0.9% | 4.00 | 2.08 | 5.7% | 12.5% | 69.3% | 43.3% | ||||||||
| 16 May 18 | Q1 Mar 18 | 1 | 31 Dec 18 | 617.92 | 28.71 | 17.59 | 2.9% | 5.00 | 6.77 | 0.8% | 0.1% | 19.0% | 7.1% | ||||||||
| 27 Feb 18 | Q4 Dec 17 | 4 | 31 Dec 17 | 613.20 | 19.87 | 21.70 | 3.5% | 6.00 | 8.36 | 6.7% | 5.2% | 506.1% | 2695.7% | ||||||||
| 15 Nov 17 | Q3 Sep 17 | 3 | 31 Dec 17 | 574.50 | 15.27 | 3.58 | 0.6% | 5.00 | 1.38 | 10.9% | 11.5% | 62.4% | 72.6% | ||||||||
| 16 Aug 17 | Q2 Jun 17 | 2 | 31 Dec 17 | 517.97 | 10.15 | 9.52 | 1.8% | 4.00 | 3.67 | 16.2% | 2.6% | 49.7% | 36.5% | ||||||||
| 16 May 17 | Q1 Mar 17 | 1 | 31 Dec 17 | 618.29 | 27.78 | 18.92 | 3.1% | 4.00 | 7.30 | 6.1% | 10.6% | 2363.5% | 3.0% | ||||||||
| 21 Feb 17 | Q4 Dec 16 | 4 | 31 Dec 16 | 582.82 | 4.07 | -0.84 | -0.1% | 3.00 | -0.32 | 13.1% | 14.3% | 106.4% | 105.2% | ||||||||
| 21 Nov 16 | Q3 Sep 16 | 3 | 31 Dec 16 | 515.22 | 19.92 | 13.06 | 2.5% | 4.00 | 5.04 | 3.1% | 1.8% | 12.9% | 34.6% | ||||||||
| 19 Aug 16 | Q2 Jun 16 | 2 | 31 Dec 16 | 531.80 | 21.49 | 14.99 | 2.8% | 5.00 | 5.79 | 4.9% | 3.7% | 18.4% | 7.5% | ||||||||
| 13 May 16 | Q1 Mar 16 | 1 | 31 Dec 16 | 559.20 | 26.54 | 18.38 | 3.3% | 4.00 | 7.10 | 17.8% | 18.5% | 14.4% | 42.2% | ||||||||
| 15 Feb 16 | Q4 Dec 15 | 4 | 31 Dec 15 | 680.15 | 23.72 | 16.06 | 2.4% | 7.00 | 6.20 | 29.7% | 8.5% | 19.6% | 56.2% | ||||||||
| 26 Nov 15 | Q3 Sep 15 | 3 | 31 Dec 15 | 524.41 | 25.34 | 19.97 | 3.8% | 9.00 | 7.71 | 2.3% | 4.5% | 23.1% | 33.5% | ||||||||
| 17 Aug 15 | Q2 Jun 15 | 2 | 31 Dec 15 | 512.85 | 25.06 | 16.22 | 3.2% | 7.00 | 6.26 | 8.7% | 2.3% | 49.0% | 1.5% | ||||||||
| 18 May 15 | Q1 Mar 15 | 1 | 31 Dec 15 | 471.90 | 38.61 | 31.79 | 6.7% | 7.00 | 12.28 | 24.8% | 0.7% | 13.4% | 21.3% | ||||||||
| 23 Feb 15 | 31/12/14 | 4 | 31/12/14 | 627.10 | 37.85 | 36.70 | 5.8% | 12.00 | 14.18 | 24.9% | 10.4% | 145.4% | 76.3% |
PHARMA Historical Dividends
PHARMA Financial Ratios
| EPS | -3.72 sen |
| Trailing PE (Sector Median: 19.3) | 0.0 |
| PEG | 0.0 |
| Altman Z | 1.1 |
| Beaver | -0.024 |
| Current Ratio | 0.59 |
| Debt-Equity (DE) Ratio | -8.49 |
| FCF Yield | -12.08 % |
| Revenue QoQ | -13.13 % |
| Revenue YoY | -1.23% |
| Profit QoQ | -89.09 % |
| Profit YoY | 42.63 % |
| Profit Margin (Sector Median: 2.4) | -1.54 % |
| ROE (ROIC: 37.08) | 20.01 % |
| Dividend Per Share (DPS) | 0.0 sen |
| Dividend Yield (DY) | 0.0 % |
PHARMA Adjusted Financial Ratios
Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports
| EPS | |
| Trailing PE (Sector Median: 19.3) | |
| Profit QoQ | |
| Profit YoY | |
| Profit Margin (Sector Median: 2.4) | |
| ROE (ROIC: 37.2) | |
| Altman Z |
PHARMA Fair Value
Weighted Average Fair Value:
| Discounted Cash Flow (DCF) 5% Growth | |
| Discounted Cash Flow (DCF) 10% Growth | |
| Relative Valuation | |
| Average Analysts FV based on 1 rating(s) |
| Graham Formula | |
| Graham Number | |
| Net Tangible Asset (NTA) | -0.19 | Consistent QR FV |
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only
Advanced Calculators
Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.
| Forward PE FV Calculator | |
| Latest Profit (adjusted) [M] | 2.8 |
| Expected Profit (Next QR) [M] | |
| Expected Profit (After QR above) [M] | |
| Expected Profit (After QR above) [M] | |
| Estimated Fair Value |
| Growth/Risk Fair Value Calculator | |
| Expected growth (%) | |
| Estimated downside / risk (%) | |
| Estimated New DCF Fair Value |
| Contract/Award Contribution Calculator | |
| Contract/Award Value (in Million) | |
| Estimated Contribution to Stock Price | |
| Estimated New DCF Fair Value |
| Profit-Based Calculator | |
| Expected Profit (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Revenue-Based Calculator | |
| Expected Revenue (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Market Pricing | |
| Expected Profit (M) | 330.12 |
| Expected Revenue (M) | 31439.92 |
| Expected Growth (%) | 38.0 |
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research
PHARMA Directors Share Purchases (Beta)
No transaction in the last 2 months.
PHARMA Summary
Market Cap: 518 M.
Market Cap Class: Small caps
Number of Shares: 1441 M.
Adjusted Float: 39.5%.
Stock highly correlated with
CATCHA (68%)
UCREST (66%)
XL (66%)
AIMFLEX (60%)
Pharmaniaga Berhad, through its subsidiaries, operates as an integrated healthcare company. It is engaged in the logistics and distribution; sale and marketing; and research, development, and manufacture of generic pharmaceuticals, as well as the supply of medical products and services; hospital equipping; and provision of information technology solutions. It is also involved in the sale and distribution of portable medical devices; contract manufacturing; and distribution and trade of pharmaceuticals products, food supplements, and diagnostics products. Pharmaniaga sells its products and services to the public and private sectors primarily in Malaysia and Indonesia. The company was founded in 1994 and is based in Shah Alam, Malaysia. Pharmaniaga Bhd operates as a member of UEM Group.
Sectors: Trading & Services, Healthcare, Pharmaceuticals, Vaccine, Penny Stocks
Code: 7081
Website: http://www.pharmaniaga.com/
Related Links: Bursa | Annual Report | Announcement
Warrant Info:
No warrants listed
PHARMA Top Shareholdings
Updated on 31-Mar-2023
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.